Marketing approval of mogamulizumab: A triumph for glyco-engineering
Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved antibodies are produced in mammalian cell lines, which yield mixtures of different glycoforms that are close to those of humans, but not fully identical. Glyco-engineering is bein...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499336/ |
| id |
pubmed-3499336 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-34993362012-11-23 Marketing approval of mogamulizumab: A triumph for glyco-engineering Beck, Alain Reichert, Janice M. Editorial Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved antibodies are produced in mammalian cell lines, which yield mixtures of different glycoforms that are close to those of humans, but not fully identical. Glyco-engineering is being developed as a method to control the composition of carbohydrates and to enhance the pharmacological properties of mAbs. The recent approval in Japan of mogamulizumab (POTELIGEO®), the first glyco-engineered antibody to reach the market, is a landmark in the field of therapeutic antibodies. Mogamulizumab is a humanized mAb derived from Kyowa Hakko Kirin’s POTELLIGENT® technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. The approval was granted April 30, 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma. Landes Bioscience 2012-07-01 /pmc/articles/PMC3499336/ /pubmed/22699226 http://dx.doi.org/10.4161/mabs.20996 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Beck, Alain Reichert, Janice M. |
| spellingShingle |
Beck, Alain Reichert, Janice M. Marketing approval of mogamulizumab: A triumph for glyco-engineering |
| author_facet |
Beck, Alain Reichert, Janice M. |
| author_sort |
Beck, Alain |
| title |
Marketing approval of mogamulizumab: A triumph for glyco-engineering |
| title_short |
Marketing approval of mogamulizumab: A triumph for glyco-engineering |
| title_full |
Marketing approval of mogamulizumab: A triumph for glyco-engineering |
| title_fullStr |
Marketing approval of mogamulizumab: A triumph for glyco-engineering |
| title_full_unstemmed |
Marketing approval of mogamulizumab: A triumph for glyco-engineering |
| title_sort |
marketing approval of mogamulizumab: a triumph for glyco-engineering |
| description |
Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved antibodies are produced in mammalian cell lines, which yield mixtures of different glycoforms that are close to those of humans, but not fully identical. Glyco-engineering is being developed as a method to control the composition of carbohydrates and to enhance the pharmacological properties of mAbs. The recent approval in Japan of mogamulizumab (POTELIGEO®), the first glyco-engineered antibody to reach the market, is a landmark in the field of therapeutic antibodies. Mogamulizumab is a humanized mAb derived from Kyowa Hakko Kirin’s POTELLIGENT® technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. The approval was granted April 30, 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma. |
| publisher |
Landes Bioscience |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499336/ |
| _version_ |
1611924520976777216 |